blocking solution protein block Search Results


99
Danaher Inc protein a g
Protein A G, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Abcam+Protein+Block/pmc06946828-91-9-11
Average 99 stars, based on 1 article reviews
protein a g - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

95
Proteintech chac1
Chac1, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/CHAC1+Antibody/ppr0425809-62-24-23
Average 95 stars, based on 1 article reviews
chac1 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

93
Rockland Immunochemicals rhodamine
Rhodamine, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Beta+Amyloid+40%2C+Peptide+Rhodamine+Conjugated/pm40571866-58-1-7
Average 93 stars, based on 1 article reviews
rhodamine - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

98
LI-COR proteinree blocking buffer
Proteinree Blocking Buffer, supplied by LI-COR, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Intercept+(TBS)+Protein-Free+Blocking+Buffer/pm42106918-458-3-6
Average 98 stars, based on 1 article reviews
proteinree blocking buffer - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

98
LI-COR intercept protein free blocking buffer
Intercept Protein Free Blocking Buffer, supplied by LI-COR, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Intercept+(PBS)+Protein-Free+Blocking+Buffer/pm42080975-92-4-9
Average 98 stars, based on 1 article reviews
intercept protein free blocking buffer - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

93
Azure Biosystems azure protein
Azure Protein, supplied by Azure Biosystems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Azure+Protein-Free+Blot+Blocking+Buffer/pm37095856-37-6-10
Average 93 stars, based on 1 article reviews
azure protein - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Rockland Immunochemicals immunohistochemistry protein blocker serum
Expression of B23 in bladder urothelial carcinoma and adjacent non-cancerous tissues, and normal human bladder and bladder cancer cells. (A) B23 expression in carcinoma and adjacent non-cancerous tissues was detected by immunohistochemical staining. (B) The percentage of B23-positive cases in 95 tumor tissues and the matched adjacent tissues was detected by <t>immunohistochemistry</t> analysis. There was a statistically significant increase in B23 staining between bladder urothelial carcinoma tissues and adjacent tissues. **P<0.01. (C) Protein and (D) mRNA expression levels of B23 in normal bladder tissues and tumors from bladder urothelial carcinoma patients were detected via western blotting and RT-qPCR, respectively. Protein and mRNA expression levels of B23 were increased in carcinoma tissues compared with adjacent tissues. (E) Protein and (F) mRNA expression levels of B23 in SV-HUC-1 normal human bladder cells and RT-4, BI-87, 253 J, J82 and T24 bladder cancer cell lines were detected by western blotting and RT-qPCR, respectively. B23 was highly expressed in bladder cancer cells. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; N, normal bladder tissues; T, tumor tissues.
Immunohistochemistry Protein Blocker Serum, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Blocking+Buffer+For+Immunohistochemistry+Serum+And+Azide+Free/pmc05364846-31-7-14
Average 93 stars, based on 1 article reviews
immunohistochemistry protein blocker serum - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
LI-COR intercept pbs protein free blocking buffer li cor
Expression of B23 in bladder urothelial carcinoma and adjacent non-cancerous tissues, and normal human bladder and bladder cancer cells. (A) B23 expression in carcinoma and adjacent non-cancerous tissues was detected by immunohistochemical staining. (B) The percentage of B23-positive cases in 95 tumor tissues and the matched adjacent tissues was detected by <t>immunohistochemistry</t> analysis. There was a statistically significant increase in B23 staining between bladder urothelial carcinoma tissues and adjacent tissues. **P<0.01. (C) Protein and (D) mRNA expression levels of B23 in normal bladder tissues and tumors from bladder urothelial carcinoma patients were detected via western blotting and RT-qPCR, respectively. Protein and mRNA expression levels of B23 were increased in carcinoma tissues compared with adjacent tissues. (E) Protein and (F) mRNA expression levels of B23 in SV-HUC-1 normal human bladder cells and RT-4, BI-87, 253 J, J82 and T24 bladder cancer cell lines were detected by western blotting and RT-qPCR, respectively. B23 was highly expressed in bladder cancer cells. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; N, normal bladder tissues; T, tumor tissues.
Intercept Pbs Protein Free Blocking Buffer Li Cor, supplied by LI-COR, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Intercept+(PBS)+Protein-Free+Blocking+Buffer/pm42001419-219-87-92
Average 94 stars, based on 1 article reviews
intercept pbs protein free blocking buffer li cor - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
Rockland Immunochemicals p29ing4
Figure 1: Expression of p33ING1b and <t>p29ING4</t> in renal cell carcinoma. (a) mRNA expression of p33ING1b and p29ING4 was increased at early and late stages of disease with higher expression of both genes at late stages of disease compared to early stages (Robson stages III/IV vs. I/II) (p33ING1b and p29ING4: stages I/II and III/IV vs. normal tissue p<0.001 and p<0.0001, respectively; p33ING1b and p29ING4: stages III/IV vs. I/II p<0.01 and p<0.001, respectively). (b) Results of the real time RT-PCR were normalized to kidney normal tissue and expressed as x-fold difference (2- ∆∆Ct). Expression of p33ING1b and p29ING4 by renal carcinoma cells was confirmed (Cy3 red; DAPI blue (nuclear counterstaining)). (c) Sections are representative of n=30 patients/group. Representative western blots of p33ING1b and p29ING4 (loading control ß-actin).
P29ing4, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/p29ING4+Peptide/10__4172_slash_2155___9899__1000511-51-13-14
Average 90 stars, based on 1 article reviews
p29ing4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

94
Rockland Immunochemicals ll 37
Figure 1: Expression of p33ING1b and <t>p29ING4</t> in renal cell carcinoma. (a) mRNA expression of p33ING1b and p29ING4 was increased at early and late stages of disease with higher expression of both genes at late stages of disease compared to early stages (Robson stages III/IV vs. I/II) (p33ING1b and p29ING4: stages I/II and III/IV vs. normal tissue p<0.001 and p<0.0001, respectively; p33ING1b and p29ING4: stages III/IV vs. I/II p<0.01 and p<0.001, respectively). (b) Results of the real time RT-PCR were normalized to kidney normal tissue and expressed as x-fold difference (2- ∆∆Ct). Expression of p33ING1b and p29ING4 by renal carcinoma cells was confirmed (Cy3 red; DAPI blue (nuclear counterstaining)). (c) Sections are representative of n=30 patients/group. Representative western blots of p33ING1b and p29ING4 (loading control ß-actin).
Ll 37, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/LL-37/pmc12323582-37-1-2
Average 94 stars, based on 1 article reviews
ll 37 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
OriGene nuclear extraction kit
Figure 1: Expression of p33ING1b and <t>p29ING4</t> in renal cell carcinoma. (a) mRNA expression of p33ING1b and p29ING4 was increased at early and late stages of disease with higher expression of both genes at late stages of disease compared to early stages (Robson stages III/IV vs. I/II) (p33ING1b and p29ING4: stages I/II and III/IV vs. normal tissue p<0.001 and p<0.0001, respectively; p33ING1b and p29ING4: stages III/IV vs. I/II p<0.01 and p<0.001, respectively). (b) Results of the real time RT-PCR were normalized to kidney normal tissue and expressed as x-fold difference (2- ∆∆Ct). Expression of p33ING1b and p29ING4 by renal carcinoma cells was confirmed (Cy3 red; DAPI blue (nuclear counterstaining)). (c) Sections are representative of n=30 patients/group. Representative western blots of p33ING1b and p29ING4 (loading control ß-actin).
Nuclear Extraction Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocking+solution+protein+block/Protein+Block+Kit/pmc06110824-80-6-9
Average 94 stars, based on 1 article reviews
nuclear extraction kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


Expression of B23 in bladder urothelial carcinoma and adjacent non-cancerous tissues, and normal human bladder and bladder cancer cells. (A) B23 expression in carcinoma and adjacent non-cancerous tissues was detected by immunohistochemical staining. (B) The percentage of B23-positive cases in 95 tumor tissues and the matched adjacent tissues was detected by immunohistochemistry analysis. There was a statistically significant increase in B23 staining between bladder urothelial carcinoma tissues and adjacent tissues. **P<0.01. (C) Protein and (D) mRNA expression levels of B23 in normal bladder tissues and tumors from bladder urothelial carcinoma patients were detected via western blotting and RT-qPCR, respectively. Protein and mRNA expression levels of B23 were increased in carcinoma tissues compared with adjacent tissues. (E) Protein and (F) mRNA expression levels of B23 in SV-HUC-1 normal human bladder cells and RT-4, BI-87, 253 J, J82 and T24 bladder cancer cell lines were detected by western blotting and RT-qPCR, respectively. B23 was highly expressed in bladder cancer cells. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; N, normal bladder tissues; T, tumor tissues.

Journal: Molecular Medicine Reports

Article Title: High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma

doi: 10.3892/mmr.2016.6033

Figure Lengend Snippet: Expression of B23 in bladder urothelial carcinoma and adjacent non-cancerous tissues, and normal human bladder and bladder cancer cells. (A) B23 expression in carcinoma and adjacent non-cancerous tissues was detected by immunohistochemical staining. (B) The percentage of B23-positive cases in 95 tumor tissues and the matched adjacent tissues was detected by immunohistochemistry analysis. There was a statistically significant increase in B23 staining between bladder urothelial carcinoma tissues and adjacent tissues. **P<0.01. (C) Protein and (D) mRNA expression levels of B23 in normal bladder tissues and tumors from bladder urothelial carcinoma patients were detected via western blotting and RT-qPCR, respectively. Protein and mRNA expression levels of B23 were increased in carcinoma tissues compared with adjacent tissues. (E) Protein and (F) mRNA expression levels of B23 in SV-HUC-1 normal human bladder cells and RT-4, BI-87, 253 J, J82 and T24 bladder cancer cell lines were detected by western blotting and RT-qPCR, respectively. B23 was highly expressed in bladder cancer cells. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; N, normal bladder tissues; T, tumor tissues.

Article Snippet: Non-specific antigen-antibody reactions were inhibited using an immunohistochemistry Protein Blocker-serum and Azide Free (MB-071-0100, Rockland Immunochemicals, Inc., Pottstown, PA, USA) for 5 min, following which the slides were washed thoroughly with PBS.

Techniques: Expressing, Immunohistochemical staining, Staining, Immunohistochemistry, Western Blot, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction

Figure 1: Expression of p33ING1b and p29ING4 in renal cell carcinoma. (a) mRNA expression of p33ING1b and p29ING4 was increased at early and late stages of disease with higher expression of both genes at late stages of disease compared to early stages (Robson stages III/IV vs. I/II) (p33ING1b and p29ING4: stages I/II and III/IV vs. normal tissue p<0.001 and p<0.0001, respectively; p33ING1b and p29ING4: stages III/IV vs. I/II p<0.01 and p<0.001, respectively). (b) Results of the real time RT-PCR were normalized to kidney normal tissue and expressed as x-fold difference (2- ∆∆Ct). Expression of p33ING1b and p29ING4 by renal carcinoma cells was confirmed (Cy3 red; DAPI blue (nuclear counterstaining)). (c) Sections are representative of n=30 patients/group. Representative western blots of p33ING1b and p29ING4 (loading control ß-actin).

Journal: Journal of Clinical & Cellular Immunology

Article Title: Tumor Suppressor Gene P29ing4 is Overexpressed and Induces a CD8 T Effector Cell Response in Human Renal Cell Carcinoma

doi: 10.4172/2155-9899.1000511

Figure Lengend Snippet: Figure 1: Expression of p33ING1b and p29ING4 in renal cell carcinoma. (a) mRNA expression of p33ING1b and p29ING4 was increased at early and late stages of disease with higher expression of both genes at late stages of disease compared to early stages (Robson stages III/IV vs. I/II) (p33ING1b and p29ING4: stages I/II and III/IV vs. normal tissue p<0.001 and p<0.0001, respectively; p33ING1b and p29ING4: stages III/IV vs. I/II p<0.01 and p<0.001, respectively). (b) Results of the real time RT-PCR were normalized to kidney normal tissue and expressed as x-fold difference (2- ∆∆Ct). Expression of p33ING1b and p29ING4 by renal carcinoma cells was confirmed (Cy3 red; DAPI blue (nuclear counterstaining)). (c) Sections are representative of n=30 patients/group. Representative western blots of p33ING1b and p29ING4 (loading control ß-actin).

Article Snippet: Analysis of single staining was performed for p33ING1 (Santa Cruz Biotechnology, CA, USA), p29ING4 (Rockland/Biomol, Hamburg, Germany) CD4, CD25, Foxp3, CD8, (Abcam, Cambridge, UK), IFN-γ (BD Pharmingen, Heidelberg, Germany), IL-2, and IL-10 (R&D Systems, Minneapolis, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control

Figure 4: p33ING1b- and p29ING4-specific T cell reactivity. Four peptides resulted in significantly increased expression of IFN-γ compared to controls, independent of tumor stage (p33ING1b (aa109-118) and aa259-268, and p29ING4 (aa149-158) and aa239-248; p<0.001) Stages I/ II (a) and Stages III/IV (b). Elispot analysis was measured as spots/5 x 105 cells/patient.

Journal: Journal of Clinical & Cellular Immunology

Article Title: Tumor Suppressor Gene P29ing4 is Overexpressed and Induces a CD8 T Effector Cell Response in Human Renal Cell Carcinoma

doi: 10.4172/2155-9899.1000511

Figure Lengend Snippet: Figure 4: p33ING1b- and p29ING4-specific T cell reactivity. Four peptides resulted in significantly increased expression of IFN-γ compared to controls, independent of tumor stage (p33ING1b (aa109-118) and aa259-268, and p29ING4 (aa149-158) and aa239-248; p<0.001) Stages I/ II (a) and Stages III/IV (b). Elispot analysis was measured as spots/5 x 105 cells/patient.

Article Snippet: Analysis of single staining was performed for p33ING1 (Santa Cruz Biotechnology, CA, USA), p29ING4 (Rockland/Biomol, Hamburg, Germany) CD4, CD25, Foxp3, CD8, (Abcam, Cambridge, UK), IFN-γ (BD Pharmingen, Heidelberg, Germany), IL-2, and IL-10 (R&D Systems, Minneapolis, USA).

Techniques: Expressing, Enzyme-linked Immunospot

Figure 5: p33ING1b- and p29ING4-specific T cell reactivity. Two peptides resulted in increased expression of IL-10 compared to controls; peptide p33ING1b (aa109-118) at all stages and p29ING4 (aa239-248) at late stages (p<0.001). Stages I/ II (a) and Stages III/IV (b). Luminex analysis was measured as pg/ml.

Journal: Journal of Clinical & Cellular Immunology

Article Title: Tumor Suppressor Gene P29ing4 is Overexpressed and Induces a CD8 T Effector Cell Response in Human Renal Cell Carcinoma

doi: 10.4172/2155-9899.1000511

Figure Lengend Snippet: Figure 5: p33ING1b- and p29ING4-specific T cell reactivity. Two peptides resulted in increased expression of IL-10 compared to controls; peptide p33ING1b (aa109-118) at all stages and p29ING4 (aa239-248) at late stages (p<0.001). Stages I/ II (a) and Stages III/IV (b). Luminex analysis was measured as pg/ml.

Article Snippet: Analysis of single staining was performed for p33ING1 (Santa Cruz Biotechnology, CA, USA), p29ING4 (Rockland/Biomol, Hamburg, Germany) CD4, CD25, Foxp3, CD8, (Abcam, Cambridge, UK), IFN-γ (BD Pharmingen, Heidelberg, Germany), IL-2, and IL-10 (R&D Systems, Minneapolis, USA).

Techniques: Expressing, Luminex

Figure 6: p33ING1b- and p29ING4-specific T cell reactivity. Evaluation of IL-2 expression revealed that only a single epitope (p29ING4 (aa149-158)) resulted in high responsiveness of T cells from RCC patients after stimulation with the peptide (stages I/II vs. III/IV p<0.001). PBMCs from healthy volunteers (n=30) had no significant IL-2 expression after stimulation with all peptide epitopes. Luminex analysis for IL-2 expression was measured as pg/ml and presented as percent stimulation index.

Journal: Journal of Clinical & Cellular Immunology

Article Title: Tumor Suppressor Gene P29ing4 is Overexpressed and Induces a CD8 T Effector Cell Response in Human Renal Cell Carcinoma

doi: 10.4172/2155-9899.1000511

Figure Lengend Snippet: Figure 6: p33ING1b- and p29ING4-specific T cell reactivity. Evaluation of IL-2 expression revealed that only a single epitope (p29ING4 (aa149-158)) resulted in high responsiveness of T cells from RCC patients after stimulation with the peptide (stages I/II vs. III/IV p<0.001). PBMCs from healthy volunteers (n=30) had no significant IL-2 expression after stimulation with all peptide epitopes. Luminex analysis for IL-2 expression was measured as pg/ml and presented as percent stimulation index.

Article Snippet: Analysis of single staining was performed for p33ING1 (Santa Cruz Biotechnology, CA, USA), p29ING4 (Rockland/Biomol, Hamburg, Germany) CD4, CD25, Foxp3, CD8, (Abcam, Cambridge, UK), IFN-γ (BD Pharmingen, Heidelberg, Germany), IL-2, and IL-10 (R&D Systems, Minneapolis, USA).

Techniques: Expressing, Luminex

Figure 7: p29ING4 presentation by MHC class I (a) and II (b) molecules. p29ING4 presentation by major histocompatibility complex (MHC) class I and II antigens was shown to be increased in RCC but not in healthy kidneys.

Journal: Journal of Clinical & Cellular Immunology

Article Title: Tumor Suppressor Gene P29ing4 is Overexpressed and Induces a CD8 T Effector Cell Response in Human Renal Cell Carcinoma

doi: 10.4172/2155-9899.1000511

Figure Lengend Snippet: Figure 7: p29ING4 presentation by MHC class I (a) and II (b) molecules. p29ING4 presentation by major histocompatibility complex (MHC) class I and II antigens was shown to be increased in RCC but not in healthy kidneys.

Article Snippet: Analysis of single staining was performed for p33ING1 (Santa Cruz Biotechnology, CA, USA), p29ING4 (Rockland/Biomol, Hamburg, Germany) CD4, CD25, Foxp3, CD8, (Abcam, Cambridge, UK), IFN-γ (BD Pharmingen, Heidelberg, Germany), IL-2, and IL-10 (R&D Systems, Minneapolis, USA).

Techniques: Immunopeptidomics